Skip to content
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Neurology

Is Immune-Mediated Necrotizing Myopathy Hereditary?

At a Glance

Immune-mediated necrotizing myopathy (IMNM) is usually an acquired autoimmune disease, not a hereditary condition passed predictably from parent to child. Genetic susceptibility may contribute, but routine genetic or antibody testing of healthy family members is not recommended.

No, immune-mediated necrotizing myopathy (IMNM) is generally not considered a hereditary disease, and it is not passed down from parent to child in a predictable pattern [1]. Rather than being a traditional genetic condition, IMNM is an acquired autoimmune disease, meaning it develops when the body’s immune system mistakenly attacks its own healthy muscle tissue [2]. Because IMNM is not typically an inherited condition, there is no medical need for routine genetic or antibody screening of your children or other healthy family members [3][4].

Autoimmune vs. Genetic Muscle Disease

When you hear the term “myopathy” (which means muscle disease), it can be easy to confuse IMNM with genetic muscle conditions like muscular dystrophy. In genetic muscular dystrophies, a specific, harmful gene variant is passed down through families, which directly causes the muscle fibers to weaken over time.

In contrast, IMNM is an acquired autoimmune disease [1]. The weakness and muscle damage in IMNM are usually associated with autoantibodies (most commonly anti-HMGCR or anti-SRP) that the immune system produces to mistakenly target your own muscle fibers [5]. Some patients do not have these specific antibodies (seronegative IMNM), but the underlying immune-mediated process is similar [6].

Because it is driven by the immune system, IMNM generally improves with immunosuppressive therapies—something that typically does not happen with genetic muscular dystrophies, although the treatment response and recovery time can vary from person to person [7].

Some genetic muscle conditions can closely mimic the symptoms of IMNM, which can sometimes lead to confusion or misdiagnosis early on [8]. However, extensive genetic testing (such as whole-exome sequencing) on patients with typical IMNM has not found a single known disease-causing inherited variant, which supports the understanding that typical IMNM is not a traditional genetic disease [9].

Genetic Susceptibility vs. Inheritance

Even though IMNM is not a directly inherited disease, genetics can play a small role. Like many autoimmune diseases, individuals can inherit a genetic susceptibility to the disease.

For example, researchers have found that patients with the anti-HMGCR subtype of IMNM frequently carry a specific immune system genetic marker called HLA-DRB1*11:01 [10][9]. Carrying this marker does not mean a person will definitely get the disease. It simply means their immune system is slightly more susceptible to developing the autoantibodies that cause IMNM if triggered by an outside factor, such as exposure to statin medications or a virus [10][9]. (Note: Not everyone with anti-HMGCR IMNM has taken a statin, and you should never stop taking a prescribed statin without first discussing the risks and alternatives with your doctor [11]).

Familial cases of IMNM appear to be extremely rare, and there is no predictable inheritance pattern established in the medical literature [12].

When Genetic Testing Might Be Considered

While genetic testing is not routine for typical IMNM, your doctor might consider genetic testing or refer you to a genetic counselor if:

  • Your diagnosis is uncertain or you do not have the typical autoantibodies (seronegative) [6].
  • Your symptoms began in early childhood or have been progressing slowly for many years [8][13].
  • You have a strong family history of muscle disease or heart conditions [14].
  • You do not respond to immunosuppressive therapies as expected [15].

What This Means for Your Family

Because IMNM is not directly passed down, there is no medical reason to routinely test healthy, asymptomatic children or family members for the disease, its autoantibodies, or any genetic markers [3][4].

However, if a child or family member ever develops unexplained muscle weakness, difficulty climbing stairs, or a persistently high creatine kinase (CK) level (a standard blood marker of muscle injury) on a routine blood test, they should be evaluated by a doctor [3][16]. This evaluation would look at a wide range of potential causes—including inherited, endocrine, or other neuromuscular issues—and would not automatically assume they have IMNM. Only as part of a thorough specialist workup might a doctor test for the specific autoantibodies associated with IMNM [4].

Seek prompt medical attention if you or a family member experience rapidly worsening weakness, trouble swallowing, shortness of breath, or dark urine.

Common questions in this guide

Could my children inherit immune-mediated necrotizing myopathy from me?
Usually not. IMNM is an acquired autoimmune disease, so it is not passed from parent to child in a predictable pattern, and familial cases appear to be extremely rare.
Should healthy relatives be screened for IMNM?
Routine genetic or antibody testing is not recommended for healthy family members who have no symptoms. A relative who develops unexplained weakness, difficulty climbing stairs, or persistently high creatine kinase should be evaluated by a clinician, who can decide which tests are appropriate.
Can genetic factors increase the chance of developing IMNM?
Yes. A marker called HLA-DRB1*11:01 is frequently found in people with anti-HMGCR IMNM and may increase immune susceptibility, but it does not guarantee that someone will develop the disease or create a predictable inheritance pattern.
When might genetic testing be useful for someone with suspected IMNM?
Testing may be considered when the diagnosis is uncertain, antibody tests are negative, symptoms began in childhood or progressed slowly, there is a strong family history of muscle or heart disease, or immunosuppressive treatment does not work as expected. A genetic counselor or neuromuscular specialist can help decide whether testing is appropriate.
Can statins or viral exposure play a role in IMNM?
In anti-HMGCR IMNM, statin exposure may be an outside trigger, and viral exposure may contribute in some cases. Not everyone with this subtype has taken a statin, and prescribed statins should not be stopped without discussing the risks and alternatives with a clinician.

Get notified when new evidence is published on Immune-mediated necrotizing myopathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (16)
  1. 1

    Immune-Mediated Necrotizing Myopathy.

    Pinal-Fernandez I, Casal-Dominguez M, Mammen AL

    Current rheumatology reports 2018; (20(4)):21 doi:10.1007/s11926-018-0732-6.

    PMID: 29582188
  2. 2

    Etiopathogenesis of Immune-Mediated Necrotizing Myopathy: A Comprehensive Review of Recent Advances.

    Gao C, Li W, Liu Q, et al.

    CNS neuroscience & therapeutics 2026; (32(5)):e70931 doi:10.1002/cns.70931.

    PMID: 42138386
  3. 3

    Pediatric Immune-Mediated Necrotizing Myopathy: A Single-Center Retrospective Cohort Study.

    Wang Y, Yang M, Zhao Y, et al.

    Pediatric neurology 2025; (167()):33-41 doi:10.1016/j.pediatrneurol.2025.03.002.

    PMID: 40203548
  4. 4

    [Immune-Mediated Necrotizing Myopathy].

    Uruha A

    Brain and nerve = Shinkei kenkyu no shinpo 2024; (76(5)):646-654 doi:10.11477/mf.1416202655.

    PMID: 38741508
  5. 5

    Immune-mediated necrotizing myopathy: clinical features and pathogenesis.

    Allenbach Y, Benveniste O, Stenzel W, Boyer O

    Nature reviews. Rheumatology 2020; (16(12)):689-701 doi:10.1038/s41584-020-00515-9.

    PMID: 33093664
  6. 6

    Peculiar clinicopathological features of immune-mediated necrotizing myopathies.

    Allenbach Y, Benveniste O

    Current opinion in rheumatology 2018; (30(6)):655-663 doi:10.1097/BOR.0000000000000547.

    PMID: 30239349
  7. 7

    A Rare Case of Anti-HMGCR and Anti-SRP-Positive Immune-Mediated Necrotizing Myopathy.

    Khan N, Kazmi Z

    Qatar medical journal 2022; (2022(1)):6 doi:10.5339/qmj.2022.6.

    PMID: 35261909
  8. 8

    Pediatric necrotizing myopathy associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies.

    Liang WC, Uruha A, Suzuki S, et al.

    Rheumatology (Oxford, England) 2017; (56(2)):287-293 doi:10.1093/rheumatology/kew386.

    PMID: 27818386
  9. 9

    Absence of Pathogenic Mutations and Strong Association With HLA-DRB1*11:01 in Statin-Naïve Early-Onset Anti-HMGCR Necrotizing Myopathy.

    Llansó L, Segarra-Casas A, Domínguez-González C, et al.

    Neurology(R) neuroimmunology & neuroinflammation 2024; (11(5)):e200285 doi:10.1212/NXI.0000000000200285.

    PMID: 39106428
  10. 10

    Genetic Biomarkers for Statin-Induced Myopathy.

    Prieto-Peña D, Urriago-Gil JD, Ocejo-Vinyals G, et al.

    International journal of molecular sciences 2025; (26(22)) doi:10.3390/ijms262211144.

    PMID: 41303626
  11. 11

    Statin-Induced Immune-Mediated Necrotizing Myopathy: An Increasingly Recognized Inflammatory Myopathy.

    Stroie OP, Boster J, Surry L

    Cureus 2020; (12(5)):e7963 doi:10.7759/cureus.7963.

    PMID: 32523820
  12. 12

    The first reported familial case of statin-induced immune-mediated necrotizing myopathy associated with anti-hydroxy-3-methylglutaryl-CoA reductase autoantibodies and HLA DRB1*11:01.

    Bronchain M, Pothen L, Taihi L, et al.

    Acta clinica Belgica 2024; 1-5 doi:10.1080/17843286.2024.2403694.

    PMID: 39279651
  13. 13

    Immune-mediated necrotizing myopathy: Unusual presentations of a treatable disease.

    Nicolau S, Milone M, Tracy JA, et al.

    Muscle & nerve 2021; (64(6)):734-739 doi:10.1002/mus.27435.

    PMID: 34617293
  14. 14

    Emerging atypical clinicopathological manifestations of immune-mediated necrotizing myopathy (IMNM).

    Skolka MP, Pinal-Fernandez I, Mammen AL, Liewluck T

    Neuromuscular disorders : NMD 2025; (50()):105363 doi:10.1016/j.nmd.2025.105363.

    PMID: 40315785
  15. 15

    Pitfalls in the diagnosis of myositis.

    Chinoy H, Lilleker JB

    Best practice & research. Clinical rheumatology 2020; (34(1)):101486 doi:10.1016/j.berh.2020.101486.

    PMID: 32063440
  16. 16

    Immune-mediated necrotising myopathy in asymptomatic patients with high creatine kinase.

    Soares IFZ, Comprido VF, Hsu BRRHS, Alves de Siqueira Carvalho A

    BMJ case reports 2020; (13(10)) doi:10.1136/bcr-2020-235457.

    PMID: 33033004

This page is for informational purposes only and does not constitute medical advice about your IMNM or your family’s risk. Ask your neurologist or genetic counselor about your individual diagnosis and whether testing is appropriate.